Black Diamond Therapeutics, Inc.
BDTX
$2.02
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 9.59% | 7.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.09% | 9.72% | |||
| Operating Income | -7.09% | -9.72% | |||
| Income Before Tax | -9.62% | 40.22% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.62% | 40.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.62% | 40.22% | |||
| EBIT | -7.09% | -9.72% | |||
| EBITDA | -7.10% | -10.16% | |||
| EPS Basic | -9.37% | 40.37% | |||
| Normalized Basic EPS | -9.32% | -13.84% | |||
| EPS Diluted | -7.94% | 39.58% | |||
| Normalized Diluted EPS | -9.32% | -13.84% | |||
| Average Basic Shares Outstanding | 0.23% | 0.25% | |||
| Average Diluted Shares Outstanding | 0.23% | 0.25% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||